Fujiwara, Takumi
Kenmotsu, Hirotsugu http://orcid.org/0000-0001-7853-5206
Naito, Tateaki
Kawamura, Takahisa
Mamesaya, Nobuaki
Kotake, Mie
Kobayashi, Haruki
Omori, Shota
Nakashima, Kazuhisa
Wakuda, Kazushige
Ono, Akira
Taira, Tetsuhiko
Murakami, Haruyasu
Omae, Katsuhiro
Mori, Keita
Endo, Masahiro
Takahashi, Toshiaki
Funding for this research was provided by:
Japan Agency for Medical Research and Development (15ck0106131h0002)
Article History
Received: 14 April 2017
Accepted: 23 April 2017
First Online: 28 April 2017
Compliance with ethical standards
:
: This study was supported by Japan Agency for Medical Research and Development (15ck0106131h0002).
: Takumi Fujiwara has received honoraria from Kyowa Hakko Kirin. Hirotsugu Kenmotsu has received research funding from AstraZeneca/MedImmune, Boehringer Ingelheim, Chugai Pharma and honoraria from AstraZeneca, Boehringer Ingelheim, Ono Pharmaceutical, Eli Lilly Japan, Chugai Parma, Taiho Pharmaceutical, Bristol-Myers Squibb, and Kyowa Hakko Kirin. Tateaki Naito has received honoraria from Ono Pharmaceutical. Takahisa Kawamura has received honoraria from AstraZeneca. Haruki Kobayashi has received honoraria from Taiho Pharmaceutical and Eli Lilly Japan. Shota Omori has received honoraria from Ono Pharmaceutical. Kazuhisa Nakashima has received honoraria from Ono Pharmaceutical, Taiho Pharmaceutical and Eli Lilly Japan. Kazushige Wakuda has received honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, AstraZeneca, Boehringer Ingelheim, Chugai Pharma and Eli Lilly Japan. Akira Ono has received honoraria from Chugai Pharma, Taiho Pharmaceutical and research funding to our institution from Takeda Pharmaceuticals and Taiho Pharmaceutical. Haruyasu Murakami has received honoraria from Nippon Boehringer Ingelheim, Pfizer, Chugai Pharma, Taiho Pharmaceutical, AstraZeneca, Eli Lilly Japan, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Novartis, and Astellas Pharma. Keita Mori has received honoraria from Ono Pharmaceutical and AstraZeneca and research funding from Boehringer Ingelheim. Masahiro Endo has received honoraria from Ono Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Daiichi sankyo and Bayer Pharmaceutical. Toshiaki Takahashi has received honoraria from Eli Lilly Japan, AstraZeneca, Chugai Pharma, Boehringer Ingelheim, Pfizer Japan, Ono Pharmaceutical and Taiho Pharmaceutical and research funding from Takeda Pharmaceuticals and MSD. For the remaining authors no conflict interested are declared.
: None of the authors has any commercial interests associated with this study or received any financial or material support for this study.
: For this type of study formal consent is not required.